The rising epidemic of type 2 diabetes mellitus associated complications is a serious cause of concern for humanity. Glucagon-like peptide-1 receptor agonists commonly abbreviated as GLP-1 RAs, emerged as a promising therapeutic class based on incretin therapy that regulates glucose metabolism through multiple mechanisms. In the present study, various investigational clinically used GLP-1 RAs have been reviewed with emphasis on their efficacy, structural modifications, adverse effects and toxicities. Various clinical trials justifying their efficacy have also been included, which highlighted the potential of GLP-1 RAs over conventional anti hyperglycaemic agents through a study of pooled effect on glycemic efficacy and weight-loss. The significant potency and appreciable safety of GLP-1 RAs manifested their potential as a logical approach for the management of type 2 diabetes.
展开▼
机译：2型糖尿病和相关并发症的流行日益严重，引起了人类的关注。胰高血糖素样肽-1受体激动剂通常缩写为GLP-1 RAs，是一种基于肠促胰岛素疗法的有前途的治疗类别，通过多种机制调节葡萄糖代谢。在本研究中，已经审查了各种研究和临床使用的GLP-1 RAs，重点是它们的疗效，结构修饰，不良反应和毒性。还纳入了各种证明其疗效的临床试验，这些试验通过对升糖疗效和减肥的综合影响的研究，强调了 GLP-1 RA 相对于传统抗高血糖药物的潜力。GLP-1 RA 的显著效力和可观的安全性表明它们作为 2 型糖尿病管理的合乎逻辑方法的潜力。
展开▼
